bioscience schreef op 2 november 2017 11:57:
Published: 07:00 CET 02-11-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176
argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017
November 2, 2017
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a key opinion leader (KOL) breakfast meeting focused on the potential of ARGX-113 to treat patients with pemphigus vulgaris (PV) on Friday, November 10, 2017 from 8:30 a.m. to 10:30 a.m. ET in New York.
The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV. Additionally, members of argenx management will present details, including trial design, of the newly initiated Phase 2 ARGX-113 study in PV.
A live webcast of the event will be available via this link. The webcast will be archived following the event and available for download on the Company's website at www.argenx.com.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 email@example.com